Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Redcare Pharmacy Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Olaf Heinrich

İcra Kurulu Başkanı

€569.2k

Toplam tazminat

CEO maaş yüzdesi	36.6%
CEO görev süresi	1.2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	8.1yrs

Son yönetim güncellemeleri

Recent updates

Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Dec 06

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Sep 07

Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Aug 02

Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Jul 17

Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

May 28

Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

May 11

We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Jan 10

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Sep 25

Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?

Jun 08

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Feb 28

Here's Why Shop Apotheke Europe (ETR:SAE) Has A Meaningful Debt Burden

Aug 01

Shop Apotheke Europe N.V.'s (ETR:SAE) About To Shift From Loss To Profit

May 11

Shop Apotheke Europe (ETR:SAE) Has A Somewhat Strained Balance Sheet

Apr 14

Insider Buying: The Shop Apotheke Europe N.V. (ETR:SAE) Chairman of the Managing Board & CEO Just Bought €96k Worth Of Shares

Mar 14

CEO Tazminat Analizi

Olaf Heinrich'un ücretlendirmesi Redcare Pharmacy'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€9m
Mar 31 2024	n/a	n/a	-€10m
Dec 31 2023	€569k	€208k	-€12m

Tazminat ve Piyasa: Olaf 'nin toplam tazminatı ($USD 630.01K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.64M ).

Tazminat ve Kazançlar: Olaf şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Olaf Heinrich (54 yo)

1.2yrs

Görev süresi

€569,150

Tazminat

Mr. Olaf Heinrich is Chief Executive Officer and Member of the Managing Board at Redcare Pharmacy NV since August 01, 2023. Mr. Heinrich served as Member of the Management Board of “DocMorris” since 2008 u...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Olaf Heinrich	CEO & Member of the Managing Board	1.2yrs	€569.15k	Veri yok
Stephan Weber	Co-Founder & Advisor	less than a year	€880.76k	Veri yok
Marc Fischer	Co-Founder & Advisor	less than a year	€880.76k	0.60% € 16.6m
Jasper F. Eenhorst	CFO & Member of Management Board	4.7yrs	€1.07m	0.013% € 371.0k
Theresa Holler	COO & Member of the Managing Board	8.8yrs	€886.24k	0.76% € 20.8m
Dirk Bruse	Chief Commercial Officer & Member of Management Board	less than a year	Veri yok	0.0094% € 258.8k
Lode Fastré	Chief Information Officer & Member of Management Board	less than a year	Veri yok	Veri yok
Monica Ambrosi	Associate Director of Investor Relations	no data	Veri yok	Veri yok
Patrick Schneider	Chief Sales Officer	no data	Veri yok	Veri yok
Beate Krosch	Director of Human Resources	no data	Veri yok	Veri yok
Nana Lohmanns	Chief E-Health Officer	no data	Veri yok	Veri yok
Jens Wolfgarten	Chief Product Officer - Retail	no data	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: RDC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jaska de Bakker	Independent Member of Supervisory Board	2.5yrs	€52.00k	Veri yok
Jerome Cochet	Independent Member of Supervisory Board	8.1yrs	€49.00k	Veri yok
Bjorn Soder	Independent Chairman of the Supervisory Board	8.1yrs	€80.00k	Veri yok
Frank Kohler	Independent Deputy Chairman of Supervisory Board	8.8yrs	€60.00k	1.6% € 44.0m
Henriette Peucker	Independent Member of Supervisory Board	3.5yrs	€49.00k	Veri yok

8.1yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RDC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.1 yıldır).

Redcare Pharmacy Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Redcare Pharmacy NV Announces Management Departures

Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024

CFO & Member of Management Board recently sold €1.0m worth of stock

Co-Founder recently sold €454k worth of stock

COO & Member of the Managing Board recently sold €331k worth of stock

COO & Member of the Managing Board recently sold €149k worth of stock

Recent updates

Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024

Second quarter 2024 earnings released

Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.

Forecast to breakeven in 2025

First quarter 2024 earnings released

Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Redcare Pharmacy NV Announces Management Departures

New minor risk - Shareholder dilution

Forecast breakeven date moved forward to 2024

Redcare Pharmacy NV to Report Q3, 2024 Results on Nov 05, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024

Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Price target increased by 7.6% to €142

Consensus EPS estimates upgraded to €0.86 loss

Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Forecast breakeven date moved forward to 2024

Consensus estimates of losses per share improve by 24%

Third quarter 2023 earnings released

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Consensus EPS estimates upgraded to €1.43 loss

CFO & Member of Management Board recently sold €1.0m worth of stock

Consensus estimates of losses per share improve by 20%

New minor risk - Share price stability

Now 21% undervalued

Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Consensus EPS estimates fall by 16%

New minor risk - Profitability

Consensus EPS estimates upgraded to €1.64 loss

Price target increased by 8.1% to €101

Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

Consensus revenue estimates increase by 19%

Price target increased by 7.5% to €99.08

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%, revenue upgraded

Co-Founder recently sold €454k worth of stock

Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

First quarter 2023 earnings released

Price target increased by 7.5% to €90.00

COO & Member of the Managing Board recently sold €331k worth of stock

Consensus EPS estimates upgraded to €2.36 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

No longer forecast to breakeven

COO & Member of the Managing Board recently sold €149k worth of stock

We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Now 22% undervalued

Forecast to breakeven in 2025

Chairman of the Managing Board & CEO recently bought €85k worth of stock

Shop Apotheke Europe N.V. to Report Fiscal Year 2022 Results on Mar 07, 2023

Price target decreased to €91.64

Third quarter 2022 earnings released

Price target decreased to €98.79

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Co-Founder recently sold €972k worth of stock

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2022 earnings released

Shop Apotheke Europe N.V. Re-Confirms Earnings Guidance for 2022

COO & Member of the Managing Board recently sold €1.5m worth of stock

Co-Founder recently sold €953k worth of stock

Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?

No longer forecast to breakeven

First quarter 2022 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

No longer forecast to breakeven